Literature DB >> 1312271

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus.

Y L Lin1, L A Borenstein, R Selvakumar, R Ahmed, F O Wettstein.   

Abstract

Immunization of rabbits with either L1, the major structural protein, or L2, a minor structural protein of cottontail rabbit papillomavirus (CRPV), protected against challenge with the virus. Neutralizing antibodies were elicited by both the L1 and L2 trpE fusion proteins. Neutralization with anti-L1 serum, however, was more efficient than with anti-L2 serum. In contrast, when tested on Western blots the immune response to L2 was stronger than to L1. Rabbits were also protected against CRPV infection by immunization with L1 expressing recombinant vaccinia virus. Sera from two of three rabbits immunized with recombinant vaccinia virus were negative on Western blots but all three were positive in ELISA's with nondenatured fusion protein or in immunoprecipitations. The results suggest that both the viral structural proteins, L1 and L2, merit consideration in the development of a vaccine against papillomavirus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312271     DOI: 10.1016/0042-6822(92)90463-y

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

1.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

2.  Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA.

Authors:  E R Jensen; R Selvakumar; H Shen; R Ahmed; F O Wettstein; J F Miller
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 3.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

4.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  T-cell response to cottontail rabbit papillomavirus structural proteins in infected rabbits.

Authors:  R Selvakumar; L A Borenstein; Y L Lin; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 8.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.

Authors:  Nicolas Combelas; Emilie Saussereau; Maxime J J Fleury; Tatiana Ribeiro; Julien Gaitan; Diego F Duarte-Forero; Pierre Coursaget; Antoine Touzé
Journal:  J Transl Med       Date:  2010-03-24       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.